M-I (CAS: )
Background Information of M-I
M-I is a metabolism of TAK-875. TAK-875 is a G protein-coupled receptor 40 agonist.
Storage Condition of M-I
Quality Control and Spectral Data
Mechanism and Indications
||Sponsor & Collaborators
Structure Information of M-I
Other Form Products of M-I
Recommended Products in Same Target
Recommended Products in the Same Indication
Chemical and Physical Properties
.Kogame A, et al. Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2018 Mar 20:1-41.
1. The absorption, distribution, metabolism and excretion of fasiglifam were investigated in rats, dogs, and humans. 2. The absolute oral bioavailability of fasiglifam was high in all species (> 76.0%). 3. After oral administration of [14C]fasiglifam, the administered radioactivity was quantitatively recovered and the major route of excretion of radioactivity was via feces in all species. 4. Fasiglifam was a major component in the plasma and feces in all species. Its oxidative metabolite (M-I) was observed as a minor metabolite in rat and human plasma (< 10% of plasma radioactivity). In human plasma, hydroxylated fasiglifam (T-1676427), the glucuronide of fasiglifam (fasiglifam-G), and the glucuronide of M-I were detected as additional minor metabolites (< 2% of plasma radioactivity). None of these metabolites were specific to humans. Fasiglifam-G was the major components in the rat and dog bile. 5. In vitro cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) reaction phenotyping indicated that oxidation (to form M-I and T-1676427) and glucuronidation of fasiglifam are mainly mediated by CYP3A4/5 and UGT1A3, respectively. 6. Fasiglifam and fasiglifam-G are substrates of BCRP and Mrp2/MRP2, respectively. 7. Glucuronidation of fasiglifam-G was found to be the predominant elimination pathway of fasiglifam in all species tested, including humans.